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ABSTRACT
Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular 
success in anticancer therapy in the recent years. In contrast, no small molecules with 
cellular activity have been reported so far. Here we provide evidence that small molecules 
are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of 
Jurkat T-lymphocytes. The two optimized small-molecule inhibitors of the PD-1/PD-
L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to 
human PD-L1 and block its interaction with PD-1, when tested on isolated proteins. The 
compounds present low toxicity towards tested cell lines and block the interaction of 
soluble PD-L1 with the cell surface-expressed PD-1. As a result, BMS-1001 and BMS-
1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated 
activation of T-lymphocytes. Moreover, the compounds were effective in attenuating 
the inhibitory effect of the cell surface-associated PD-L1. We also determined the X-ray 
structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed 
features that may be responsible for increased potency of the compounds compared to 
their predecessors. Further development may lead to the design of an anticancer therapy 
based on the orally delivered immune checkpoint inhibition.
INTRODUCTION 
Anticancer therapies targeting immune checkpoint 
receptors have witnessed a spectacular success in the 
last years. Antibodies blocking CTLA4 interaction with 
CD80, and, to even more extent, PD-1/PD-L1 interaction, 
provided unprecedented results. This merited accelerated 
approvals by regulatory agencies, offering a real cure to 
certain formerly lethal cancers [1–5].
PD-1 is expressed on activated T cells [6] and 
transduces inhibitory signal which antagonizes the 
activating T-cell receptor (TCR) and CD28 axis [7]. The 
inhibitory signal is provided by PD-L1, the ligand of PD-
1, which is naturally expressed on the antigen-presenting 
cells (APCs) and in a variety of tissues [8]. In normal 
conditions this mitigates T-cell response, best demonstrated 
in PD-L1-deficient mice where T-cell responses are 
markedly enhanced [9]. The immunosuppressive function 
of PD-L1 is utilized by cancer cells to avoid being killed 
by the T cells recognizing neoantigens at their surface 
[7, 10]. Prolonged exposure to PD-L1 leads to T cell 
exhaustion characterized by a sustained poor effector 
function [11, 12]. This is a common histological picture 
in which tumor tissue is infiltrated by immune cells which 
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recognize, but are unable to eradicate the cancer cells 
[13, 14]. 
Recent data demonstrate that PD-L1 not only is 
overexpressed on the surface of cancer cells, but the level 
of soluble PD-L1 (sPD-L1) is elevated in the plasma of 
some cancer patients [15, 16]. It is unclear if this is related 
to shedding from the cancer cells or other mechanisms, 
but the elevated level of sPD-L1 correlates with poor 
prognosis [17, 18]. Of note, like the membrane-bound PD-
L1, sPD-L1 has also been shown to be a negative regulator 
of activated T cells [17–19].
Antagonizing the PD-1/PD-L1 interaction reverts the 
exhausted phenotype of T cells and allows efficient killing 
of cancer cells [20, 21]. The utility of this approach has 
been demonstrated in clinics and has become a spectacular 
success in the recent years [1–3, 22]. In just 3 years the 
U.S. Food and Drug Administration (FDA) has approved 
two anti PD-1 antibodies: nivolumab (Opdivo, Bristol-
Myers Squibb) and pembrolizumab (Keytruda, Merck), 
and three anti-PD-L1 antibodies, atezolizumab (Tecentriq, 
Genentech/Roche), durvalumab (Imfinzi, AstraZeneca) and 
avelumab (Bavencio, EMD Serono, Inc.), rising hope in 
patients suffering from cancers, which were deadly prior 
to the introduction of checkpoint inhibitors.
The development of small-molecular weight 
inhibitors is expected to bring a number of profits in the field 
of the PD-1/PD-L1 immune checkpoint blockade (ICB). 
This is due to several advantages of small molecules over 
therapeutic antibodies, which are: lower production costs, 
higher stability, improved tumor penetration, amenability 
for oral administration and elimination of immunogenicity 
issues [22]. However, development of small-molecule 
antagonists is lagging behind that of antibodies primarily 
due to the challenge of targeting a relatively flat and highly 
hydrophobic PD-1/PD-L1 interaction surface [23]. Only 
a single class of small molecules has been convincingly 
shown to directly antagonize this interaction [23]. These 
are the compounds designed and patented by Bristol-Myers 
Squibb (BMS) [24, 25]. We have recently demonstrated that 
these BMS compounds bind to human PD-L1 and block 
its interaction with human PD-1 [26]. Here we show that 
these small-molecule compounds are indeed capable of 
restoring the activity of T cells by disrupting the PD-1/
PD-L1 interaction. We also present structural details of 
the interaction between PD-L1 and two improved BMS 
compounds, BMS-1001 and BMS-1166. This opens 
exciting possibilities for future development of orally 
bioavailable anticancer ICB therapies using small-molecule 
inhibitors.
RESULTS
Compound selection
Based on the two recent Bristol-Myers Squibb 
patents [24, 25], the selection of the BMS compounds was 
done to obtain high diversity of the chemical structures 
along all modifications of distal, flexible moieties 
exposed to the solvent (Figure 1A). The compounds 
were synthesized as described previously [26] with 
modifications. All compounds were tested for the 
interaction with PD-L1 using the 1H-15N HMQC NMR 
titration experiment with positive results, as reported 
elsewhere [26] and in this manuscript (see below). In 
order to verify the blockade of the PD-1/PD-L1 interaction 
by the compounds an NMR-based AIDA was performed 
[27, 28]. Upon the PD-L1 binding the broadening of 
1H-15N resonance signals of the 15N labeled PD-1 is 
observed due to an increased transverse relaxation rate 
of the higher molecular weight entities [27, 28]. This 
results in disappearance of the HMQC resonance signals 
in the spectrum (Figure 1B). All the compounds efficiently 
disrupted the complex formed by human PD-1 and PD-L1 
proteins, as visualized by the restoration of narrow 1H-15N 
signals of PD-1 ([26] and (Figure 1B)).
Analysis of unspecific toxicity of the BMS 
compounds
To define the maximum admissible concentrations 
of BMS compounds for the use in the cell-based assays, 
the toxicity of the compounds was evaluated with the 
use of metabolic activity assay. For this, modified Jurkat 
T cells (ECs) used in all further assays were exposed to 
the increasing concentration of the tested compounds 
for 48 h. Considerable differences in the toxicity of the 
tested compounds were noted. The most toxic compounds 
(BMS-37 and -242) showed EC50 between 3 and 6 µM. 
BMS-1001 and BMS-1166 were significantly less 
toxic, with EC50 values of 33.4 and 40.5 µM. Other two 
compounds (BMS-8 and -200) showed moderate toxicity 
(Figure 2A). Low toxicity of BMS-1001 and -1166 
compounds was confirmed using modified CHO-K1 cells 
(aAPCs; Supplementary Figure 1). These two compounds 
were considered the most suitable for the cell-based 
experiments and used as references in all further analyses.
BMS-1001 and BMS-1166 antagonize the 
inhibitory effect of PD-1/PD-L1 immune 
checkpoint on T cell activation
A T lymphocyte-like cell line (Jurkat) modified 
to constitutively express PD-1 and carrying a luciferase 
reporter gene driven by TCR-inducible NFAT response 
element (Effector Cells, ECs) was used in T cell activation 
experiments. When antigen-presenting surrogate CHO 
cells, constitutively expressing the TCR agonist and PD-
L1 (aAPCs) are presented to these ECs in co-culture, 
TCR signaling is repressed by PD-1 and the reporter 
remains silenced. Agents efficiently interfering with the 
PD-1/PD-L1 interaction activate the expression of the 
reporter gene resulting in the increase in luminescence 
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intensity. Clinically relevant PD-1-antagonizing antibodies 
(nivolumab and pembrolizumab) and the PD-L1-blocking 
antibodies (atezolizumab and durvalumab) release 
TCR signaling with EC50 values in range of 0.333–1.15 
nM (Figure 2B, 2D). Both BMS-1001 and BMS-1166 
dose-dependently induced the activity of luciferase, 
demonstrating the antagonizing potential towards the 
PD-1/PD-L1 immune checkpoint at the cell interface 
(Figure 2C). Nevertheless, the effect of BMS compounds 
was significantly less pronounced compared to the tested 
antibodies, with EC50 values in three-digit nanomolar range 
and lower maximal cell activation levels, represented by 
lower RLUmax values (Figure 2D). BMS-200 did not affect 
the reporter expression at the concentrations below the 
cytotoxic level.
BMS-1001 and BMS-1166 antagonize the 
inhibitory effect of soluble PD-L1 on T cells
Increased level of sPD-L1 is thought to negatively 
affect the T cell anticancer response [17–19]. This is because 
sPD-L1 provides the same inhibitory signal as the cell 
surface PD-L1. This is evident when ECs are simultaneously 
treated with anti-CD3 and sPD-L1. Anti-CD3 induced 
the activation of ECs, manifested in increased reporter 
expression (Figure 3A). Concurrent presence of sPD-L1 
decreased reporter expression to about half of that observed 
for the anti-CD3 antibody alone (Figure 3A). The two 
sPD-L1 muteins, bearing mutations of the key residues at 
the interaction surface, PD-L1(A121Q) and PD-L1(Y56A, 
M115A), failed to bind to PD-1 in NMR-monitored direct 
titration and AIDA-NMR (Supplementary Figure 2A–2E), 
and did not inhibit the anti-CD3 mediated activation of ECs 
(Supplementary Figure 2F). This proves that the modulatory 
effect of sPD-L1 towards the activation of ECs is mediated 
specifically through the engagement of PD-1. Moreover, 
the anti-PD-1 antibody nivolumab abrogated the effect of 
sPD-L1, further supporting the involvement of the PD-1 
immune checkpoint receptor (Figure 3A).
To evaluate the potential of BMS compounds 
in abrogating the inhibitory effect of sPD-L1 on the 
activation of T cells, sPD-L1 was pre-incubated with 
tested compounds and presented to ECs together with the 
anti-CD3-activating antibody. BMS-1001 and -1166 dose-
dependently abolished the inhibition of ECs stimulation 
by sPD-L1 (Figure 3A). Importantly, at the highest 
concentrations (2- and 5-fold molar excess over sPD-L1) 
the compounds completely restored cell activation back 
to the level observed for anti-CD3 alone. Other tested 
compounds showed intermediate activities. The two most 
cytotoxic compounds (BMS-37 and BMS-242) presented 
unspecific decrease in the readout level at the highest 
concentrations used (Figure 3A).
To test if the observed effect of BMS compounds was 
directly associated with the decreased sPD-L1 recruitment 
to the cell surface of the PD-1-expressing cells, a His-
tagged sPD-L1 was labeled with the Ni-NTA-conjugated 
fluorescent dye and flow cytometry analysis was performed. 
When ECs were contacted with labeled sPD-L1, a clear 
staining was observed (Figure 3B). Pre-incubation of 
labeled sPD-L1 with PD-L1-blocking antibody durvalumab 
or atezolizumab significantly decreased the staining of ECs 
contrary to the control, non-specific antibody (Figure 3B). 
Additionally, the two PD-L1 mutants, PD-L1(A121Q) and 
PD-L1(Y56A/M115A), demonstrated reduced binding to 
ECs as evidenced by weaker cell staining compared to 
PD-L1(wt) (Supplementary Figure 2G). This demonstrates 
that the labeled sPD-L1 utilizes the canonical interaction 
surface to bind PD-1 receptor. Pre-incubation of sPD-L1 
with BMS-1001 or BMS-1166 significantly decreased the 
intensity of staining (Figure 3B), again demonstrating that 
both compounds interfere with sPD-L1 interaction with 
PD-1 receptor exposed at the cell surface.
Structural basis of the interaction of BMS-1001 
and BMS-1166 with hPD-L1 
To decipher the structural details of the interaction 
of improved BMS compounds with PD-L1, we crystallized 
and solved the structure of BMS-1166 in complex with the 
Ig-like V-type domain of human PD-L1 at the resolution of 
2.2 Å (Table 1). The asymmetric unit contains four protein 
molecules organized in two dimers, and each dimer 
harbors a single inhibitor molecule in a cylindrical tunnel 
at the interface of two monomers. Such organization of the 
dimer is similar to that we previously observed for BMS-
202 [26]. The deep hydrophobic pocket harboring BMS-
202 is transformed into a tunnel in the PD-L1/BMS-1166 
structure by rotation of the ATyr56 sidechain (the monomer 
molecules are annotated by subscripts A, B according to 
their chain arrangement in the crystal structure of the 
dimer) by 40 degrees (Figure 4). Not only this removes 
the steric hindrance, but provides additional interactions 
between ATyr56 and the 2,3-dihydro-1,4-benzodioxine 
moiety of the inhibitor. 
Induced pockets are attractive targets for inhibitor 
design. To confirm the binding mode and vulnerability of 
the Tyr56 sidechain to ligand-induced changes, we solved 
the crystal structure of BMS-1001 in complex with sPD-L1 
(Table 1; Supplementary Figure 3). The arrangement of 
ATyr56 sidechain and a resulting tunnel shaped binding 
pocket are identical in both structures (Figure 4).
At the other side of the tunnel the 3-cyanobenzyl 
substituent of BMS-1166 is stabilized through the ring 
π-stacking with BTyr123. Additionally, hydrogen bonds are 
formed between the cyan group and Nε atom of the side 
chain of BArg125. The (2R, 4R)-4-hydroxypyrrolidine-2-
carboxylic acid substituent is stabilized through hydrogen 
bond with NH2 group of BLys124 side chain (Figure 4 
and Supplementary Figure 4). In BMS-1001, the (2R)-2-
amino-3-hydroxypropanoic acid moiety forms hydrogen 
bonds with the carbonyl of AAsp122 sidechain and 
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additional water-mediated hydrogen bond with the NH2 
group of ALys124 and mainchain carbonyl of ATyr123. The 
3-cyanobenzyl substituent provides additional hydrophobic 
contacts with ATyr123 aromatic ring and AArg125 sidechain 
(Figure 4 and Supplementary Figure 4).
Defining the minimal BMS-1166 fragment with 
the PD-L1 binding ability
For further compound development it is of high 
importance to define the minimal fragments essential for 
the binding to the target protein. For this, BMS-1166 and 
its fragments were tested for interaction with PD-L1 using 
NMR method. From the six decomposition fragments 
tested, four retained PD-L1 binding potential (Figure 5). 
The analysis revealed that a two aromatic ring system 
(compound 4, Figure 5) is the minimal fragment of BMS-
1166 responsible for the PD-L1 binding.
BMS-1001 and BMS-1166 induce PD-L1 
dimerization in solution
The formation of solution-stable PD-L1 dimers 
in the presence of BMS compounds was characterized 
Figure 1: Structures and the PD-1/PD-L1 blocking potential of BMS compounds. (A) The structures of BMS compounds 
tested in this study. The original numbering found in the patents [24, 25] is used. (B) BMS-1166 dissociates a preformed PD-1/PD-L1 
complex, as shown by the NMR-based Antagonist Induced Dissociation Assay (AIDA). 1H-15N HMQC spectra are shown for the 15N 
labeled PD-1 (left) and the complex of the 15N labeled PD-1 and unlabeled PD-L1 alone (center) and after addition of BMS-1166 (right). 
Linewidth broadening, observed as loss of resonance signals in the central panel, indicates increased transverse relaxation rates associated 
with the complex formation. At the PD-L1:BMS-1166 molar ratio of 4:1, BMS-1166 efficiently disrupted the PD-1/PD-L1 complex, as 
visualized by the restoration of the 1H-15N signals of PD-1.
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Figure 2: Cytotoxicity and activity of BMS compounds in PD-1/PD-L1 checkpoint assay. (A) Cytotoxicity of BMS 
compounds against the PD-1 Effector Cells was tested using metabolic activity assay following the 48 h treatment of the cells with the 
indicated compounds. The presented EC50 values (right panel) are means ± SEM from the three independent experiments (left panel shows 
a representative result). (B, C) Activities of reference antibodies (B) and BMS compounds (C) in alleviating the effect of PD1/PD-L1 
checkpoint on TCR-mediated T cell activation are expressed as the level of luciferase activity (for details see Materials and Methods). The 
graphs present relative luminescence normalized to the DMSO-treated controls and are representative of the three independent experiments. 
(D) The result of the fitting of Hill model to experimental data presented on panels B and C. EC50 values represent half maximal effective 
concentrations, and RLUmax values represent maximal relative luminescence values, and illustrate the potency of the listed molecules in 
restoring the activity of ECs in the assay.
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previously for BMS-202 [26]. The crystal structures of 
BMS-1001 and -1166 bound to PD-L1 indicated similar 
properties of the compounds, but this required verification 
by in-solution assays. Initial clues were provided by 
direct NMR titration of 15N labeled PD-L1 where both 
BMS-1001 and BMS-1166 induced linewidth broadening 
indicative of significant increase in molecular weight of 
the analyzed species upon compound addition (Figure 5). 
This was verified by a crosslinking experiment. sPD-L1 
preincubated in the presence of a cross-linking agent 
(bis(sulfosuccinimidyl)suberate, BS3) migrated in SDS-
PAGE as a single band corresponding to monomeric 
protein. Preincubation in the same conditions with the 
addition of BMS-1001 resulted in two bands in SDS-
PAGE analysis, corresponding to sPD-L1 monomer and 
a dimer (Supplementary Figure 5A). sPD-L1 dimerization 
in the presence of BMS was further confirmed by a size 
exclusion chromatography, where the retention time of 
sPD-L1 was significantly shortened in the presence of 
BMS-1001 and the change in retention time was indicative 
of dimer formation (Supplementary Figure 5B).
Model of BMS-induced dimerization of PD-L1
Our structural and biochemical results suggest that 
BMS compounds induce the formation of PD-L1 dimers. 
Inside the dimer a single BMS molecule interacts with 
two distinct sites on PD-L1, within PD-1 interaction 
surfaces of both protomers. Further optimization of BMS 
compounds, especially towards the molecules which 
Table 1: Data collection and refinement statistics (molecular replacement)
BMS-1001 BMS-1166
Data collection
Wavelength (Å) 0.9795 0. 91842
Resolution range 46.01–2.01 (2.09–2.01) 45.94–2.20 (2.28–2.20)
Space group P 21 21 21 P 21 21 21
Cell dimensions
    a, b, c (Å) 39.88 84.67 164.41 40.53 84.61 164.12
    α, β, γ (°) 90 90 90 90 90 90
Rmerge 0.065 (0.452) 0.050 (0.240)
I / σI 22.3 (5.3) 20 (6.3)
Completeness (%) 99.8 (97.7) 100 (100)
Redundancy 12.7 (12.7) 6.3 (6.8)
Refinement
Resolution (Å) 2.01 2.2
No. reflections 37778 (3648) 29563 (2925)
Rwork / Rfree 0.209/0.262 0.213/0.2563
No. atoms 4359 4210
    Protein 3945 3862
    Ligand/ion 96 100
Ramachandran favored (%) 97 97
Ramachandran allowed (%) 3 3
Ramachandran outliers (%) 0 0
B-factors
    Protein 43.91 46.14
    Ligand/ion 53.40 56.19
    Water 47.11 44.62
R.m.s. deviations
    Bond lengths (Å) 0.017 0.023
    Bond angles (°) 1.9 1.67
*Values in parentheses are for the highest-resolution shell.
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Figure 3: BMS compounds restore the sPD-L1-supressed activation of Jurkat T-cells. (A) Effector Cells were activated 
for 24 h with the anti-CD3 antibody alone or in the presence of sPD-L1, pre-incubated with nivolumab (nivol.), DMSO or the BMS 
compounds. The activity of luciferase, expressed in response to TCR-mediated induction of NFAT-responsive promoter, was determined 
as an indicator of cell activation. BMS compounds dose-dependently restored the activation, pre-blocked by the presence of sPD-L1. The 
graphs present mean ± SEM from at least three independent experiments. Statistical significance was evaluated using a one-way ANOVA 
with the Tukey’s post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001. (B, C) The binding of the fluorescently-labeled sPD-L1 (PD-L1-Atto) 
to PD-1 expressing cells determined using flow cytometry. PD-L1-Atto was pre-incubated with tested compounds prior to staining. Cell 
staining is blocked in the presence of the anti-PD-L1 antibody (durvalumab, durva. or atezolizumab, atezo.) and BMS compounds. MFI – 
Geo Mean Fluorescence Intensity values. The bar graphs present mean ± SEM from three independent experiments. For the statistics, t-test 
was used: **p < 0.01, ***p < 0.001.
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action would not require the engagement of two PD-L1 
entities, requires defining the energetically favorable 
binding mode of BMS at the PD-L1 surface. Docking 
simulations of BMS-1001 and -1166 at separate protomers 
consistently show a single energetically favorable binding 
mode identical to that observed in the crystal structure of 
APD-L1, but not BPD-L1 (Figure 6). This suggests a model 
where BMS compounds transiently bind PD-L1 in a mode 
characteristic for APD-L1 protomer, and such a preformed 
complex recruits the second PD-L1 molecule. Such model, 
if confirmed experimentally, would direct the development 
of BMS compound towards monomeric binders.
DISCUSSION
According to recent reports and clinical data, 
targeting the PD-1/PD-L1 immune checkpoint is an 
important and effective strategy for the treatment of 
diverse cancer types [1–3]. The use of monoclonal 
antibodies have evidenced the therapeutic potential of 
Figure 4: BMS-1166 induces binding cleft opening. (A) Arrangement of the molecules in the crystal structure – two PD-L1 
molecules form a single pocket accommodating BMS compound. A close-up presents the position of the side-chain of the Tyr56 in BMS-8 
(gray) and BMS-1166 (yellow/blue) containing structures. (B) The 2,3-dihydro-1,4-benzodioxine moiety of BMS-1001 and BMS-1166 
induces the previously absent side-chain movement that triggers transformation of the binding pocket into the binding tunnel across the 
transverse vertical axis of the dimer. The panel visualizes surface representation of the dimer with the visible binding cleft (left, BMS-8/
PD-L1 complex) and the binding tunnel (center and right for the BMS-1001/PD-L1 and BMS-1166/PD-L1 complexes, respectively). PD-
L1 molecules forming the dimer are colored blue and green for chains A and B, respectively. Compounds are shown as yellow sticks.
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PD-1/PD-L1 blockade, but further development of clinical 
strategies targeting this immune checkpoint would be 
much facilitated by the introduction of other molecule 
types, devoid of the known drawbacks of monoclonal 
antibodies.
Several classes of non-antibody molecules have 
been patented in the recent years, including one group 
of small-molecule inhibitors, disclosed by Bristol-Myers 
Squibb in the two consecutive patents [24, 25], but very 
little data on activity was provided. In order to verify the 
activity of these disclosed groups of small molecules, 
we have selected and synthesized six representative 
compounds with one of the best Kd values measured 
by Homogenous Time-Resolved Fluorescence (HTRF) 
in vitro binding assay [24, 25]. Our study shows the 
biological activity of some of these small molecules 
at the cellular level and provides the background for 
their evaluation in further pre-clinical studies. At the 
same time issues and limitations of these particular 
compounds are highlighted, necessitating further 
improvement.
We have shown previously that the compounds 
BMS-8, BMS-37 and BMS-242 bind to PD-L1 and 
efficiently dissociate the human PD-1/PD-L1 complex 
in vitro [26]. Here we demonstrate that the two optimized 
BMS compounds, BMS-1001 and BMS-1166, present 
significantly improved cytotoxic properties, allowing 
the use of higher concentrations. In addition, unlike the 
Figure 5: Decomposition of BMS-1166. BMS-1166 (1) or its fragments (2-6) were tested for the interaction with PD-L1 (blue) 
using 1H-15N HMQC NMR method. The spectra determined in presence of compounds (1)-(4) display line-broadening (red), indicative of 
compound-induced formation of a higher molecular weight PD-L1 complex. Compounds (5) and (6) induced no changes in the spectra even 
at molar excess, indicating the lack of interaction.
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three compounds described earlier, BMS-1001 and -1166 
present the potential of restoring the activation of effector 
Jurkat T cells, attenuated by both soluble and membrane-
bound PD-L1 presented by antigen-presenting cells. 
Although the potential of the compounds in restoring 
the activation of effector cells is significantly lower 
Figure 6: The prediction of BMS-1001 and -1166 binding sites on PD-L1 surface. Molecular docking simulations were 
performed to predict the favored binding sites of BMS compounds to PD-L1 protein. APD-L1 and BPD-L1 protomers were extracted from 
the co-crystal structures of BMS-1001/PD-L1 and BMS-1166/PD-L1 and used as templates (receptors) for the docking of appropriate BMS 
compound (ligand). The best docking results (represented by the purple compounds) are compared with crystallographic arrangements 
(represented by the green compounds). (A, D) For both BMS compounds, when APD-L1 protomer was investigated, the preferred molecular 
docking results corresponded well to the binding modes determined from crystallographic data. (B, E) When BPD-L1 protomer was selected, 
molecular docking simulations suggested an opposite orientation of the compounds to the one defined by crystal structure analysis (among 
the 10 best results not a single resembled the BMS orientation determined from crystal structures of BMS/BPD-L1). (C, F) The alignment 
of BPD-L1 protomer to the APD-L1 protomer revealed a significant resemblance of the binding mode of BMS compounds docked to BPD-L1 
and the ones revealed from the crystals for APD-L1 protomer.
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than that observed for the therapeutic antibodies, further 
optimization based on our structural data may lead to the 
development of more potent molecules.
Both structural and biochemical data suggest the 
formation of dimers of sPD-L1 in the presence of BMS 
compounds. This unique formation of PD-L1 dimers may 
facilitate the inhibition of PD-1/PD-L1 interaction, as the 
dimerization engages PD-1-binding surfaces of both PD-
L1 protomers. Since the level of soluble PD-L1 is increased 
in the serum of cancer patients and correlates with poor 
prognosis [15, 16], and sPD-L1 is able to interfere with the 
activation of blood T cells [17–19], the functional elimination 
of sPD-L1 could provide a positive therapeutic role by 
increasing the immune competence of T cells circulating 
in the blood. Additionally, this might have a meaning in 
cancer lesions, where cancer-derived sPD-L1 would block 
membrane-bound PD-L1 molecules in the presence of the 
compounds evaluated in this study, or membrane-bound PD-
L1 molecules would reciprocally block each other at the cell-
cell interface of cancer cells. Nevertheless, these potential 
mechanisms require further experimental verification.
Our structural results show that the tested BMS 
compounds force the conformational changes at the surface 
of PD-L1 molecule upon binding. Both conformational 
changes and additional interaction sub-sites absent 
in previously published structures result in improved 
interaction between the characterized compounds and the 
target protein (Figure 4). These results prove that although 
the targeting of PD-1/PD-L1 interaction with small 
molecules was considered challenging due to relatively flat 
interface of PD-1/PD-L1 interaction, it is not unfeasible. 
The plasticity of PD-L1 surface seems to be instrumental 
in designing the new compounds. The structures of BMS 
compounds reported here and in our previous studies [26] 
and the structure of PD-1/PD-L1 complex [29] may serve 
as starting points for the design of new molecular scaffolds 
based on molecular docking strategies. On top of that, our 
binding model suggests the more favorable BMS binding 
pose to start with. 
Collectively, our results advocate for PD-1/PD-
L1-blocking potential of the evaluated BMS compounds 
and present a likely mode of this inhibition by forcing the 
dimerization of PD-L1 molecules.
MATERIALS AND METHODS
Therapeutic antibodies
Following antibodies were used: anti-PD-1 antibody 
nivolumab (MDX-1106, trade name: Opdivo, Bristol-
Myers Squibb), anti-PD-1 antibody pembrolizumab 
(MK-3475, trade name: Keytruda, Merck & Co., Inc.), 
anti-PD-L1 antibody atezolizumab (MPDL3280A, trade 
name: Tecentriq, Genentech/Roche) and anti-PD-L1 
antibody durvalumab (MEDI4736, trade name: Imfinzi, 
AstraZeneca Pharmaceuticals LP).
Synthesis of Bristol-Myers Squibb compounds
Six small-molecule compounds disclosed by 
Bristol-Myers Squibb were tested in respect to their 
biological activities in disrupting of the PD-1/PD-L1 
interaction. The compounds were synthesized according to 
procedures described in BMS patents [24, 25] with minor 
modifications as described elsewhere [26]. The identity 
and purity of all compounds was evaluated by 1H NMR, 
13C NMR, high-resolution mass spectrometry (HRMS) and 
UPLC/MS.
Protein expression and purification
Expression and purification of human PD-L1 
(residues 18–134, C-terminal His-tag) and human PD-1 
(residues 33–150, Cys93 exchanged to serine) was carried 
out as described previously [26]. A single residue A121Q 
hPD-L1 mutant and double mutant Y56A, M115A were 
prepared using site-directed mutagenesis. The constructs 
were verified by sequencing. The mutants were purified 
using the same protocol as the wild-type protein. The 
purity of the proteins was evaluated by SDS-PAGE and 
folding was examined using NMR spectroscopy.
NMR measurements
Uniform 15N labelling was obtained by expressing 
proteins in the M9 minimal medium containing 15NH4Cl 
as the sole nitrogen source. For NMR measurements the 
buffer was exchanged by gel filtration to PBS pH 7.4 
(PD-L1) or 25 mM sodium phosphate containing 100 
mM NaCl pH 6.4 (PD-1). 10% (v/v) of D2O was added 
to the samples to provide the lock signal. All spectra were 
recorded at 300K using a Bruker Avance III 600 MHz 
spectrometer. The interaction of the compounds with 
PD-L1 was evaluated by monitoring the perturbations 
in chemical shifts of NMR resonances in the 1H-15N 2D 
HMQC upon titration with the compound. The ability 
of tested compounds to dissociate PD-L1/PD-1 was 
evaluated using the Antagonist Induced Dissociation 
Assay (AIDA) [27, 28]. In brief, 15N-labeled PD-1 (0.2 
mM) was slightly overtitrated with the unlabeled PD-L1. 
The compounds were aliquoted into the resulting mixture. 
During the experiment the 1H-15N signals were monitored 
by the HMQC. 
Cell lines
To verify the potency of BMS compounds in the 
inhibition of the PD-1/PD-L1 interactions, a cell-based model 
of the PD-1/PD-L1 immune checkpoint blockade was used. 
In the assay, two model cell lines are utilized: the artificial 
Antigen-Presenting Cells (PD-L1+ aAPC/CHO-K1 cells, 
called aAPCs) overexpressing TCR ligand and PD-L1, and 
T cell surrogate, a modified Jurkat T cell line overexpressing 
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PD-1 and carrying a luciferase reporter under the control 
of NFAT promoter (PD-1 Effector Cells, called ECs) [30]. 
The cells were obtained from Promega and cultured in the 
RPMI 1640 medium (Lonza) supplemented with 10% Fetal 
Bovine Serum (BioWest), 100 U/ml Penicillin and 100 U/
ml Streptomycin. Additionally, the cells were propagated in 
a constant presence of Hygromycin B (50 µg/ml) and G418 
(250 µg/ml) to provide a stable expression of the introduced 
genetic constructs. The two latter antibiotics were omitted 
in the experiments. Overexpression of PD-1 on ECs and 
PD-L1 on aAPCs was verified by flow cytometry (not 
shown) and the presence of the luciferase-expressing gene 
was verified by monitoring luciferase activity following 
anti-CD3 antibody stimulation. Antibiotic selection, flow 
cytometry and reporter expression served as cell line 
authentication method. The cells were periodically tested 
and found negative for Mycoplasma contamination using 
PCR-based method [31].
Cytotoxicity assay
5 000 ECs were seeded on transparent 96-well 
plates and cultured for 48 h in the presence of increasing 
concentrations of the BMS compounds or DMSO as a 
control (the concentration of DMSO was kept constant in 
all samples). Following the treatment, a metabolic activity 
test was performed with the use of Biolog Redox Dye Mix 
MB (BioLog), according to the manufacturer’s instructions.
PD1/PD-L1 checkpoint assay
The aAPCs were seeded in white 96-well plates at the 
density of 10 000 per well in the culture medium 24 h prior 
to the assay. On the day of the assay, 3.5x serial dilutions of 
the antibodies were prepared in the RPMI 1640-containing 
1% FBS. Serial dilutions of BMS compounds were prepared 
in DMSO and formulated in RPMI 1640-containing 1% 
FBS. By this, the concentration of DMSO was kept constant 
in all samples. 95 μl of the medium was removed from the 
wells and the cells were overlaid with 40 μl of the compound 
dilutions. 20 000 of ECs were added to each well in 40 μl 
RPMI 1640 containing 1% FBS. Following 6 h incubation 
at 37°C, the plates were equilibrated at room temperature 
for 10 min and 80 μl of the Bio-Glo reagent (Promega) 
was added to each well. After incubation for 10 min, 
luminescence was quantified using FlexStation 3 (Molecular 
Devices). Half maximal effective concentrations (EC50) and 
maximal luminescence values (RLUmax) were determined by 
fitting the Hill equation to the experimental data.
PD-1/sPD-L1 effector assay 
For the evaluation of the BMS impact on T cell 
inhibition by soluble PD-L1, the ECs were stimulated with 
the anti-CD3 antibody in the presence of the recombinant 
human sPD-L1. For this, the 96-well white flat bottom plates 
were coated overnight at 4°C with 5 µg/ml of the anti-CD3 
antibody or the isotype control solution in PBS. The antibody 
solution was removed and the plates were washed 3 times 
with PBS and dried. sPD-L1 (aa 18–134) was diluted in PBS 
supplemented with the penicillin/streptomycin solution (100 
U/ml final concentration each) in the presence of the BMS 
compounds or a corresponding volume of DMSO. Then, 15 
µl of the solution was added to each well of the antibody-
coated plate. ECs were centrifuged and diluted to 50 000 per 
ml, and 60 µl of the cell solution was added to each well. 
The final concentration of sPD-L1 was 10 µg/ml (0.6 µM). 
The final concentrations of the BMS compounds were: 0.12, 
0.3, 1.2 and 3 µM, giving the following BMS:sPD-L1 molar 
ratios: 1:5, 1:2, 2:1 and 5:1. The cells were cultured for 24 
h and the luciferase activity assay was performed using the 
Bio-Glo Luciferase Assay System (Promega) according to 
the manufacturer’s instructions.
Flow cytometry measurements
Binding of sPD-L1 (aa 18–134) to ECs was 
evaluated by flow cytometry. The His-tagged PD-L1 
protein or its mutants were stained with NTA-Atto 647 
N fluorescent dye (Sigma Aldrich) for 2 h at 22°C, at 8:1 
molar ratio (protein:dye). PD-L1-Atto was formulated 
in 150 µl PBS with the tested compounds or antibodies. 
The samples were incubated for 30 min at 4°C in the 
dark. Meanwhile, ECs were centrifuged, washed with 
PBS and suspended in fresh PBS at concentration of 
1 × 106 cells per ml. 50 µl of ECs was added to each 
sample and incubated on ice for additional 60 min. The 
final concentrations of the components were: 25 µg/ml of 
PD-L1 (1.5 µM), 125 µg/ml the anti-PD-L1 antibodies and 
control antibodies and 1 µM of the BMS compounds. The 
samples were analyzed using the BD FACS Verse flow 
cytometer and BD FACSuite v1.0.6 software.
Crystallization of the hPD-L1/BMS-1001 and 
hPD-L1/BMS-1166 complexes
Purified proteins in 10 mM Tris (pH 8.0) containing 
20 mM NaCl, were concentrated to 5 mg/ml, mixed 
with the inhibitor in 1:3 molar ratio (protein:compound) 
and clarified by centrifugation at 15 000 × g for 10 min. 
Supernatant was used for screening using a sitting-drop 
vapor diffusion method. Diffraction-quality crystals were 
obtained at room temperature from 0.1 M Tris pH 8.5 
containing 0.2 M magnesium chloride and 30% (w/v) PEG 
4000 for the hPD-L1/BMS-1001 complex and from 0.01 
M Tris pH 8.4 containing 0.28 M sodium chloride and 
27% (w/v) PEG 4000 for hPD-L1/BMS-1166 complex.
Structure solution and refinement
The X-ray diffraction data were collected at the 
PETRA III P11 beamline at DESY (Hamburg, Germany; 
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[32]) and on the BL14.1 beamline operated by the 
Helmholtz-Zentrum Berlin (HZB) at the BESSY II (Berlin-
Adlershof, Germany; [33]) for hPD-L1/BMS-1001 and 
hPD-L1/BMS-1166, respectively. The data were indexed 
and integrated using XDS [34, 35]. Scaling and merging 
was performed using Aimless [36]. Molecular replacement 
was calculated using Phaser [37] and PDB 5C3T as a search 
model. The model building was performed using Coot 
[38] and refinement was performed in Phenix [39]. Water 
molecules were added automatically and inspected manually 
Model validation was performed using Molprobity [40].
Complex analysis by gel filtration 
Superdex S75 10/30 HR column was equilibrated 
with 10 mM Tris pH 8.0 containing 20 mM NaCl. The 
column was calibrated with globular protein standards. 
The retention time of hPD-L1 (4 mg/ml) was determined. 
hPD-L1/inhibitor complexes were formed at 3:1 
(inhibitor:protein) molar ratio, incubated for 15 min at 
room temperature and clarified by centrifugation for 10 
min at 15 000 × g. The samples were analyzed in the same 
manner as the apo-hPD-L1. 
Cross-linking experiment
hPD-L1 was concentrated to 10 µM in PBS pH 7.4 
and mixed with BMS-1001 or BMS-1166 in the 1:1 molar 
ratio, followed by the addition of the BS3 cross-linking 
reagent at 0.25, 0.5 or 1mM final concentration (Thermo 
Scientific). After 30-min incubation at room temperature, 
the reaction was quenched by the addition of Tris pH 
7.5 to the final concentration of 25 mM. Control sample 
contained hPD-L1 and 1 mM BS3 reagent. The samples 
were analyzed by SDS-PAGE.
Molecular docking
Docking of BMS compounds at the surface of PD-
L1 was performed using Hex 8.0.0 with default parameters 
[41]. APD-L1 and BPD-L1 protomers were extracted from 
co-crystal structures with BMS-1001 or -1166, described 
in this manuscript, and used as receptors. BMS compounds 
were also extracted from the co-crystal structures, served 
as ligands and treated as rigid.
Accession numbers
Coordinates and structure factors were deposited 
in the Protein Data Bank with accession numbers 5NIU 
(BMS-1001) and 5NIX (BMS-1166).
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